NOVARTIS PHARMS CORP Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS PHARMS CORP, and what generic alternatives to NOVARTIS PHARMS CORP drugs are available?
NOVARTIS PHARMS CORP has two approved drugs.
There are nine US patents protecting NOVARTIS PHARMS CORP drugs.
There are one hundred and ninety-eight patent family members on NOVARTIS PHARMS CORP drugs in fifty-two countries and thirty-six supplementary protection certificates in fifteen countries.
Summary for NOVARTIS PHARMS CORP
International Patents: | 198 |
US Patents: | 9 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for NOVARTIS PHARMS CORP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | 7,468,390*PED | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | RX | Yes | Yes | 11,135,192 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | 9,517,226 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NOVARTIS PHARMS CORP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | 6,465,504 | ⤷ Try a Trial |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,596,750 | ⤷ Try a Trial |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | 6,596,750 | ⤷ Try a Trial |
Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,465,504 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARMS CORP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
International Patents for NOVARTIS PHARMS CORP Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1212242 | ⤷ Try a Trial |
Portugal | 3294283 | ⤷ Try a Trial |
Hungary | E054885 | ⤷ Try a Trial |
Denmark | 1948158 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVARTIS PHARMS CORP Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1948158 | CA 2016 00023 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN SOM SACUBITRIL-VALSARTAN-NATRIUMSALTKOMPLEKS; REG. NO/DATE: EU/1/15/1058 (C(2015)8288) 20151123 |
1948158 | PA2016017,C1948158 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SAKUBITRILAS/VALSARTANAS; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
1467728 | C01467728/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: SACUBRITIL UND VALSARTAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65673 17.09.2015 |
2340828 | LUC00195 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.